ENSG00000029363 |
BCLAF1 |
clear cell renal carcinoma |
sequence_alteration |
0.6977% (9/1290) |
1 entry |
ENSG00000029363 |
BCLAF1 |
head and neck squamous cell carcinoma |
missense_variant |
0.639% (4/626) |
2 entries |
ENSG00000029363 |
BCLAF1 |
head and neck squamous cell carcinoma |
sequence_alteration |
0.639% (4/626) |
2 entries |
ENSG00000029363 |
BCLAF1 |
esophageal squamous cell carcinoma |
sequence_alteration |
1.333% (9/675) |
3 entries |
ENSG00000029363 |
BCLAF1 |
melanoma |
missense_variant |
10.89% (11/101) |
2 entries |
ENSG00000029363 |
BCLAF1 |
clear cell renal carcinoma |
missense_variant |
0.6977% (9/1290) |
1 entry |
ENSG00000029363 |
BCLAF1 |
prostate adenocarcinoma |
sequence_alteration |
2.132% (31/1454) |
1 entry |
ENSG00000029363 |
BCLAF1 |
rectal adenocarcinoma |
missense_variant |
2.715% (6/221) |
1 entry |
ENSG00000029363 |
BCLAF1 |
bladder transitional cell carcinoma |
sequence_alteration |
1.46% (2/137) |
2 entries |
ENSG00000029363 |
BCLAF1 |
colorectal adenocarcinoma |
frameshift_variant |
2.109% (24/1138) |
2 entries |
ENSG00000029363 |
BCLAF1 |
non-small cell lung carcinoma |
missense_variant |
3.774% (2/53) |
1 entry |
ENSG00000029363 |
BCLAF1 |
small cell lung carcinoma |
missense_variant |
2.201% (7/318) |
2 entries |
ENSG00000029363 |
BCLAF1 |
ovarian serous adenocarcinoma |
sequence_alteration |
1.04% (7/673) |
2 entries |
ENSG00000029363 |
BCLAF1 |
lung adenocarcinoma |
sequence_alteration |
4.815% (56/1163) |
3 entries |
ENSG00000029363 |
BCLAF1 |
hepatocellular carcinoma |
sequence_alteration |
0.8889% (8/900) |
1 entry |
ENSG00000029363 |
BCLAF1 |
cecum adenocarcinoma |
sequence_alteration |
5.6% (7/125) |
1 entry |
ENSG00000029363 |
BCLAF1 |
lung adenocarcinoma |
stop_gained |
4.815% (56/1163) |
2 entries |
ENSG00000029363 |
BCLAF1 |
rectal adenocarcinoma |
sequence_alteration |
2.715% (6/221) |
1 entry |
ENSG00000029363 |
BCLAF1 |
basal cell carcinoma |
sequence_alteration |
31.03% (18/58) |
1 entry |
ENSG00000029363 |
BCLAF1 |
colorectal adenocarcinoma |
missense_variant |
2.109% (24/1138) |
2 entries |
ENSG00000029363 |
BCLAF1 |
brain glioblastoma |
sequence_alteration |
0.9719% (9/926) |
1 entry |
ENSG00000029363 |
BCLAF1 |
skin melanoma |
sequence_alteration |
7.032% (68/967) |
3 entries |
ENSG00000029363 |
BCLAF1 |
basal cell carcinoma |
missense_variant |
31.03% (18/58) |
1 entry |
ENSG00000029363 |
BCLAF1 |
rectal adenocarcinoma |
stop_gained |
2.715% (6/221) |
1 entry |
ENSG00000029363 |
BCLAF1 |
squamous cell lung carcinoma |
missense_variant |
2.362% (18/762) |
2 entries |
ENSG00000029363 |
BCLAF1 |
colon adenocarcinoma |
missense_variant |
3.74% (27/722) |
5 entries |
ENSG00000029363 |
BCLAF1 |
melanoma |
sequence_alteration |
10.89% (11/101) |
2 entries |
ENSG00000029363 |
BCLAF1 |
esophageal adenocarcinoma |
missense_variant |
2.278% (10/439) |
1 entry |
ENSG00000029363 |
BCLAF1 |
pancreatic ductal adenocarcinoma |
missense_variant |
1.271% (16/1259) |
1 entry |
ENSG00000029363 |
BCLAF1 |
esophageal squamous cell carcinoma |
missense_variant |
1.333% (9/675) |
2 entries |
ENSG00000029363 |
BCLAF1 |
esophageal adenocarcinoma |
sequence_alteration |
2.278% (10/439) |
1 entry |
ENSG00000029363 |
BCLAF1 |
Merkel cell skin cancer |
sequence_alteration |
6.667% (2/30) |
2 entries |
ENSG00000029363 |
BCLAF1 |
Central Nervous System Lymphoma |
missense_variant |
22.22% (2/9) |
1 entry |
ENSG00000029363 |
BCLAF1 |
prostate carcinoma |
sequence_alteration |
2.113% (9/426) |
1 entry |
ENSG00000029363 |
BCLAF1 |
skin melanoma |
missense_variant |
7.032% (68/967) |
5 entries |
ENSG00000029363 |
BCLAF1 |
lung adenocarcinoma |
frameshift_variant |
4.815% (56/1163) |
1 entry |
ENSG00000029363 |
BCLAF1 |
breast carcinoma |
missense_variant |
0.4252% (6/1411) |
1 entry |
ENSG00000029363 |
BCLAF1 |
ovarian serous adenocarcinoma |
missense_variant |
1.04% (7/673) |
2 entries |
ENSG00000029363 |
BCLAF1 |
squamous cell lung carcinoma |
sequence_alteration |
2.362% (18/762) |
1 entry |
ENSG00000029363 |
BCLAF1 |
small cell lung carcinoma |
sequence_alteration |
2.201% (7/318) |
2 entries |
ENSG00000029363 |
BCLAF1 |
adenosquamous lung carcinoma |
missense_variant |
27.27% (3/11) |
1 entry |
ENSG00000029363 |
BCLAF1 |
lung adenocarcinoma |
missense_variant |
4.815% (56/1163) |
3 entries |
ENSG00000029363 |
BCLAF1 |
colon adenocarcinoma |
sequence_alteration |
3.74% (27/722) |
4 entries |
ENSG00000029363 |
BCLAF1 |
prostate adenocarcinoma |
missense_variant |
2.132% (31/1454) |
3 entries |
ENSG00000029363 |
BCLAF1 |
cecum adenocarcinoma |
missense_variant |
5.6% (7/125) |
2 entries |
ENSG00000029363 |
BCLAF1 |
prostate carcinoma |
missense_variant |
2.113% (9/426) |
2 entries |
ENSG00000029363 |
BCLAF1 |
hepatocellular carcinoma |
missense_variant |
0.8889% (8/900) |
1 entry |
ENSG00000029363 |
BCLAF1 |
esophageal squamous cell carcinoma |
frameshift_variant |
1.333% (9/675) |
2 entries |
ENSG00000029363 |
BCLAF1 |
colorectal adenocarcinoma |
sequence_alteration |
2.109% (24/1138) |
2 entries |
ENSG00000029363 |
BCLAF1 |
colon adenocarcinoma |
stop_gained |
3.74% (27/722) |
1 entry |
ENSG00000029363 |
BCLAF1 |
metaplastic breast carcinoma |
missense_variant |
3.922% (2/51) |
1 entry |
ENSG00000029363 |
BCLAF1 |
breast ductal adenocarcinoma |
missense_variant |
3.596% (21/584) |
1 entry |
ENSG00000029363 |
BCLAF1 |
rectal adenocarcinoma |
frameshift_variant |
2.715% (6/221) |
1 entry |
ENSG00000029363 |
BCLAF1 |
mucosal melanoma |
sequence_alteration |
7.143% (1/14) |
1 entry |
ENSG00000029363 |
BCLAF1 |
colon adenocarcinoma |
conservative_inframe_deletion |
3.74% (27/722) |
1 entry |
ENSG00000029363 |
BCLAF1 |
small cell lung carcinoma |
frameshift_variant |
2.201% (7/318) |
1 entry |
ENSG00000029363 |
BCLAF1 |
Mantle cell lymphoma |
sequence_alteration |
4.878% (2/41) |
1 entry |
ENSG00000029363 |
BCLAF1 |
Extraskeletal Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000029363 |
BCLAF1 |
prostate carcinoma |
stop_gained |
2.113% (9/426) |
1 entry |
ENSG00000029363 |
BCLAF1 |
Pleural Biphasic Mesothelioma |
missense_variant |
3.333% (1/30) |
1 entry |
ENSG00000029363 |
BCLAF1 |
esophageal squamous cell carcinoma |
stop_gained |
1.333% (9/675) |
1 entry |
ENSG00000029363 |
BCLAF1 |
female breast carcinoma |
missense_variant |
0.3745% (1/267) |
1 entry |
ENSG00000029363 |
BCLAF1 |
osteosarcoma |
missense_variant |
1.724% (2/116) |
1 entry |
ENSG00000029363 |
BCLAF1 |
clear cell renal carcinoma |
frameshift_variant |
0.6977% (9/1290) |
1 entry |
ENSG00000029363 |
BCLAF1 |
melanoma |
frameshift_variant |
10.89% (11/101) |
1 entry |
ENSG00000029363 |
BCLAF1 |
cecum adenocarcinoma |
frameshift_variant |
5.6% (7/125) |
1 entry |
ENSG00000029363 |
BCLAF1 |
Brain Stem Glioblastoma |
sequence_alteration |
1.786% (1/56) |
1 entry |
ENSG00000029363 |
BCLAF1 |
basal cell carcinoma |
stop_gained |
31.03% (18/58) |
1 entry |
ENSG00000029363 |
BCLAF1 |
brain glioblastoma |
conservative_inframe_deletion |
0.9719% (9/926) |
1 entry |
ENSG00000029363 |
BCLAF1 |
colorectal adenocarcinoma |
stop_gained |
2.109% (24/1138) |
1 entry |
ENSG00000029363 |
BCLAF1 |
Pancreatic Acinar Cell Carcinoma |
sequence_alteration |
5.0% (1/20) |
1 entry |
ENSG00000029363 |
BCLAF1 |
head and neck squamous cell carcinoma |
stop_gained |
0.639% (4/626) |
1 entry |
ENSG00000029363 |
BCLAF1 |
cecum adenocarcinoma |
stop_gained |
5.6% (7/125) |
1 entry |
ENSG00000029363 |
BCLAF1 |
non-small cell lung carcinoma |
sequence_alteration |
3.774% (2/53) |
1 entry |
ENSG00000029363 |
BCLAF1 |
Pancreatic Acinar Cell Carcinoma |
stop_gained |
5.0% (1/20) |
1 entry |
ENSG00000029363 |
BCLAF1 |
Mantle cell lymphoma |
missense_variant |
4.878% (2/41) |
1 entry |
ENSG00000029363 |
BCLAF1 |
papillary renal cell carcinoma |
stop_gained |
0.2985% (1/335) |
1 entry |
ENSG00000029363 |
BCLAF1 |
colon adenocarcinoma |
frameshift_variant |
3.74% (27/722) |
1 entry |
ENSG00000029363 |
BCLAF1 |
head and neck squamous cell carcinoma |
frameshift_variant |
0.639% (4/626) |
1 entry |
ENSG00000029363 |
BCLAF1 |
osteosarcoma |
sequence_alteration |
1.724% (2/116) |
1 entry |
ENSG00000029363 |
BCLAF1 |
mucosal melanoma |
missense_variant |
7.143% (1/14) |
1 entry |
ENSG00000029363 |
BCLAF1 |
Central Nervous System Lymphoma |
sequence_alteration |
22.22% (2/9) |
1 entry |
ENSG00000029363 |
BCLAF1 |
Merkel cell skin cancer |
missense_variant |
6.667% (2/30) |
1 entry |
ENSG00000029363 |
BCLAF1 |
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
0.2252% (1/444) |
1 entry |
ENSG00000029363 |
BCLAF1 |
oral squamous cell carcinoma |
missense_variant |
0.4878% (1/205) |
1 entry |
ENSG00000029363 |
BCLAF1 |
large cell lung carcinoma |
missense_variant |
5.556% (1/18) |
1 entry |